Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.

A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...

Fosamax was acquired in 2021 by Organon, which agreed to indemnify Merck against liability from the lawsuits. (Pierson, 9/20) Reuters: J&J Unit Files For Bankruptcy To Advance $10 Billion Talc ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Organon & Co (OGN) stock saw a decline, ending the day at $19.97 which represents a decrease of $-0.58 or -2.82% from the prior close of $20.55. The stock opened at $20.51 and touched a low of $19.42 ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.